Ionis Historical Income Statement
| IONS Stock | USD 41.97 1.12 2.60% |
Historical analysis of Ionis Pharmaceuticals income statement accounts such as Total Revenue of 827 M or Gross Profit of 817.4 M can show how well Ionis Pharmaceuticals performed in making a profits. Evaluating Ionis Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Ionis Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Ionis Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Ionis Pharmaceuticals is a good buy for the upcoming year.
Ionis |
About Ionis Income Statement Analysis
Ionis Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Ionis Pharmaceuticals shareholders. The income statement also shows Ionis investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Ionis Pharmaceuticals Income Statement Chart
Ionis Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Ionis's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Ionis Pharmaceuticals revenue and expense. Ionis Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Ionis Pharmaceuticals' Research Development is comparatively stable compared to the past year. Selling General Administrative is likely to gain to about 244.2 M in 2024, despite the fact that EBIT is likely to grow to (328.1 M). Add Fundamental
Total Revenue
Total revenue comprises all receipts Ionis Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Ionis Pharmaceuticals. It is also known as Ionis Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Cost Of Revenue
Cost of Revenue is found on Ionis Pharmaceuticals income statement and represents the costs associated with goods and services Ionis Pharmaceuticals provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Ionis Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Ionis Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ionis Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Ionis Stock please use our How to Invest in Ionis Pharmaceuticals guide.At this time, Ionis Pharmaceuticals' Research Development is comparatively stable compared to the past year. Selling General Administrative is likely to gain to about 244.2 M in 2024, despite the fact that EBIT is likely to grow to (328.1 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 829M | 984M | 1.1B | 1.2B | Cost Of Revenue | 11M | 14M | 9.1M | 8.7M |
Ionis Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Ionis Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Ionis Pharmaceuticals income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 16.0M | 17.2M | 9M | (150M) | 22.5M | 23.6M | |
| Interest Expense | 49M | 45.0M | 4.3M | 8.1M | 75.6M | 79.4M | |
| Total Revenue | 1.1B | 729M | 810M | 587M | 787.6M | 827.0M | |
| Gross Profit | 1.1B | 717M | 799M | 573M | 778.5M | 817.4M | |
| Other Operating Expenses | 757M | 901M | 840M | 998M | 1.1B | 1.2B | |
| Operating Income | 366M | (172M) | (30M) | (411M) | (353.7M) | (336.0M) | |
| Ebit | 366M | (172M) | (30M) | (411M) | (345.3M) | (328.1M) | |
| Ebitda | 382.0M | (154.8M) | (21M) | (561M) | (322.8M) | (306.7M) | |
| Cost Of Revenue | 4M | 12M | 11M | 14M | 9.1M | 8.7M | |
| Total Operating Expenses | 753M | 889M | 829M | 984M | 1.1B | 1.2B | |
| Net Income | 294M | (487M) | (29M) | (270M) | (366.3M) | (348.0M) | |
| Income Before Tax | 347M | (170M) | (30M) | (258M) | (334.0M) | (317.3M) | |
| Total Other Income Expense Net | (19M) | 2M | (5.1M) | 153M | 101.2M | 106.3M | |
| Income Tax Expense | 44M | 317M | (1M) | 12M | 32.3M | 33.9M | |
| Research Development | 466M | 535M | 643M | 833M | 899.6M | 944.6M | |
| Selling General Administrative | 287M | 354M | 170.9M | 150.3M | 232.6M | 244.2M | |
| Net Income From Continuing Ops | 303.3M | (486.8M) | (28.6M) | (269.7M) | (366.3M) | (348.0M) | |
| Non Operating Income Net Other | 29.7M | 47.0M | 10.4M | 160.3M | 184.4M | 193.6M | |
| Net Income Applicable To Common Shares | 294.1M | (451.3M) | (28.6M) | (269.7M) | (242.7M) | (230.6M) | |
| Minority Interest | (11.3M) | (58.8M) | 9.1M | (35.5M) | 1.2M | 0.0 | |
| Tax Provision | 43.5M | 317M | (1M) | 11.7M | 32.3M | 33.9M | |
| Net Interest Income | (48.8M) | (45.0M) | (9.2M) | (8.1M) | (81.5M) | (77.4M) | |
| Reconciled Depreciation | 16.0M | 17.2M | 19.6M | 22.1M | 22.5M | 18.6M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ionis Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Ionis Stock please use our How to Invest in Ionis Pharmaceuticals guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Complementary Tools for Ionis Stock analysis
When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |
Is Ionis Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ionis Pharmaceuticals. If investors know Ionis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ionis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.44) | Earnings Share (2.56) | Revenue Per Share 5.501 | Quarterly Revenue Growth 1.136 | Return On Assets (0.08) |
The market value of Ionis Pharmaceuticals is measured differently than its book value, which is the value of Ionis that is recorded on the company's balance sheet. Investors also form their own opinion of Ionis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ionis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ionis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ionis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ionis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ionis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ionis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.